Therapy with gastrin antibody in the Zollinger-Ellison syndrome.
The therapeutic effectiveness of parenterally administered rabbit antigastrin antibody was evaluated in a patient with the Zollinger-Ellison syndrome who had a fasting serum gastrin level of 3020 pg/ml and a basal gastric acid secretion of 48.9 mEq/hr. Control globulin reduced gastric secretion to 32 mEq/hr. Gastrin antibody reduced it futher to 8.7 mEq/hr. Betazole hydrochloride which was given 75 min after administration of gastrin antibody stimulated acid secretion to 57.2 mEq/hr. One day later basal acid secretion was uninhibited although some antibody activity was present in the patient's serum. The results suggested that gastrin antibody acutely inhibited basal but not betazole-stimulated secretion.
D000328:Adult; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage*; D000918:Antibody Specificity; D001667:Binding, Competitive; D004285:Dogs; D005260:Female; D005755:Gastrins / Q000037:antagonists & inhibitors / Q000097:blood / Q000276:immunology*; D006801:Humans; D007112:Immunity, Maternally-Acquired; D007275:Injections, Intravenous; D011817:Rabbits; D015043:Zollinger-Ellison Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology
D000906:Antibodies; D005755:Gastrins